BusinessBuild an industry-leading, fast-growing large medical market by discovering, developing and commercializing expertise and new proprietary technologies.

Introduction

OPKO Health, Inc., was originally incorporated in Delaware in October 1991. The company is a diversified healthcare company seeking to establish an industry leading position in the large and rapidly growing healthcare market. The company's pharmaceutical businesses include Rayaldee, approved by the Food and Drug Administration for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D deficiency, and Somatrogon, a weekly injection of human growth hormone, The company has partnered with Pfizer on the further development and commercialization of Somatrogon.